Riverbridge Partners LLC Has $512,000 Stock Position in Certara, Inc. $CERT

Key Points

• Riverbridge Partners LLC significantly reduced its stake in Certara, Inc. by 97.9% during the 2nd quarter, now holding only 43,741 shares worth $512,000.
• Institutional investors and hedge funds own 73.96% of Certara's stock, with several firms, including Deutsche Bank AG and Two Sigma Investments LP, increasing their holdings during the last quarter.
• Certara reported $0.07 earnings per share for the latest quarter, missing analyst expectations, but showed a revenue increase of 12.1% year-over-year.

Riverbridge Partners LLC reduced its stake in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 97.9% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 43,741 shares of the company's stock after selling 2,004,778 shares during the period. Riverbridge Partners LLC's holdings in Certara were worth $512,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of CERT. Deutsche Bank AG raised its holdings in Certara by 1,227.0% during the 4th quarter. Deutsche Bank AG now owns 27,323 shares of the company's stock worth $291,000 after buying an additional 25,264 shares during the period. Two Sigma Investments LP raised its holdings in Certara by 20.1% during the 4th quarter. Two Sigma Investments LP now owns 377,524 shares of the company's stock worth $4,021,000 after buying an additional 63,246 shares during the period. Two Sigma Advisers LP raised its holdings in Certara by 35.7% during the 4th quarter. Two Sigma Advisers LP now owns 87,500 shares of the company's stock worth $932,000 after buying an additional 23,000 shares during the period. Squarepoint Ops LLC raised its holdings in Certara by 62.7% during the 4th quarter. Squarepoint Ops LLC now owns 94,433 shares of the company's stock worth $1,006,000 after buying an additional 36,386 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Certara by 16.8% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 263,574 shares of the company's stock worth $2,807,000 after buying an additional 37,870 shares during the period. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Certara

In related news, insider Leif E. Pedersen sold 51,224 shares of the firm's stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $10.92, for a total value of $559,366.08. Following the completion of the transaction, the insider directly owned 73,979 shares of the company's stock, valued at approximately $807,850.68. This trade represents a 40.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 2.33% of the company's stock.

Certara Price Performance

NASDAQ:CERT opened at $11.55 on Friday. Certara, Inc. has a 1-year low of $8.64 and a 1-year high of $15.69. The company has a current ratio of 2.16, a quick ratio of 2.16 and a debt-to-equity ratio of 0.27. The firm has a fifty day simple moving average of $10.83 and a 200 day simple moving average of $11.26. The stock has a market capitalization of $1.86 billion, a PE ratio of 231.05 and a beta of 1.43.

Certara (NASDAQ:CERT - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a net margin of 1.97% and a return on equity of 5.11%. The firm had revenue of $104.57 million during the quarter, compared to the consensus estimate of $104.14 million. During the same period in the prior year, the business posted $0.07 earnings per share. Certara's quarterly revenue was up 12.1% compared to the same quarter last year. On average, research analysts expect that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on CERT shares. Morgan Stanley started coverage on shares of Certara in a report on Thursday, July 3rd. They set an "equal weight" rating and a $16.00 target price on the stock. UBS Group lowered their price objective on shares of Certara from $17.50 to $15.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. KeyCorp lowered their price objective on shares of Certara from $18.00 to $15.00 and set an "overweight" rating on the stock in a report on Monday, July 14th. Finally, Zacks Research upgraded shares of Certara from a "strong sell" rating to a "hold" rating in a report on Friday, September 5th. Five investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $15.14.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.